RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Plus Therapeutics Stock

Plus Therapeutics P/S 2024

Plus Therapeutics P/S

1.29

Ticker

PSTV

ISIN

US72941H4002

WKN

A2PPX6

As of Oct 7, 2024, Plus Therapeutics's P/S ratio stood at 1.29, a -48.4% change from the 2.5 P/S ratio recorded in the previous year.

The Plus Therapeutics P/S history

Plus Therapeutics Aktienanalyse

What does Plus Therapeutics do?

Plus Therapeutics Inc is a US pharmaceutical company specializing in the development and marketing of novel targeted cancer therapies. The company was founded in 2002 under the name Cygnus Biosciences Inc and changed its name to Plus Therapeutics Inc in 2018. Since then, the company has been listed on NASDAQ under the ticker symbol "PSTV". The history of the company dates back to 1998 when scientist James R. Baker Jr. founded Cygnus Biosciences to advance his cancer medicine research. Baker is considered one of the leading experts in the field of nanotechnology cancer research and has made a number of groundbreaking discoveries in this field. The business model of Plus Therapeutics is based on the development and marketing of novel cancer drugs, particularly those based on nanotechnology. The company aims to improve the effectiveness and safety of cancer drugs and thus contribute to improving the quality of life of cancer patients. Plus Therapeutics is divided into several divisions, including nanomedicine, biotechnology, and pharmaceuticals. In the field of nanomedicine, the company develops products based on targeted drug release. The goal is to transport the active ingredients in such a way that they specifically reach the site of the tumor and can have their full effect there. In the field of biotechnology, the company is developing new technologies to further improve the effectiveness and safety of cancer drugs. In the field of pharmaceuticals, Plus Therapeutics focuses on the development of cancer drugs based on nanotechnology. An important milestone in the history of Plus Therapeutics was the development of the drug DocePLUS, which is based on nanotechnology and can be used against breast cancer. DocePLUS has been approved by the FDA and is currently being tested in clinical trials. The company is also working on the development of other cancer drugs, including those that can be used against other types of cancer. Plus Therapeutics has an experienced management team and works closely with leading experts in the field of cancer medicine. The company has formed a number of partnerships and collaborations with other pharmaceutical companies and research institutions in the US and worldwide to advance its research and development. Overall, Plus Therapeutics aims to revolutionize cancer treatment and help cancer patients achieve a higher quality of life. With its innovative research and the goal of developing new targeted and more effective therapies, the company is on track to achieve this goal. Plus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Plus Therapeutics's P/S Ratio

Plus Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Plus Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Plus Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Plus Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Plus Therapeutics stock

What is the price-to-earnings ratio of Plus Therapeutics?

The price-earnings ratio of Plus Therapeutics is currently 1.29.

How has the price-earnings ratio of Plus Therapeutics changed compared to last year?

The price-to-earnings ratio of Plus Therapeutics has increased by -48.4% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Plus Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Plus Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Plus Therapeutics affect the company?

An increase in the price-earnings ratio of Plus Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Plus Therapeutics affect the company?

A decrease in the price-earnings ratio of Plus Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Plus Therapeutics?

Some factors that influence the price-earnings ratio of Plus Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Plus Therapeutics pay?

Over the past 12 months, Plus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Plus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Plus Therapeutics?

The current dividend yield of Plus Therapeutics is .

When does Plus Therapeutics pay dividends?

Plus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Plus Therapeutics?

Plus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Plus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Plus Therapeutics located?

Plus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Plus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Plus Therapeutics from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Plus Therapeutics pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Plus Therapeutics in the year 2023?

In the year 2023, Plus Therapeutics distributed 0 USD as dividends.

In which currency does Plus Therapeutics pay out the dividend?

The dividends of Plus Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Plus Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Plus Therapeutics

Our stock analysis for Plus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Plus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.